Junshi Biosciences
Toripalimab(Junshi Biosciences)은 Gastric Cancer 표적 항체로, Metastatic Colorectal Cancer; Liver Metastases 영역에서 개발·상용화 중입니다. 작용기전: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Phase 3 후기 임상 단계입니다. ClinicalTrials.gov 기준 93건의 관련 임상이 등록되어 있습니다. 차별점: novel safety signals were identified.
Gastric Cancer
Metastatic Colorectal Cancer; Liver Metastases
Recruiting
NK cells, increased circulating CD8+ Tem and Teff cells and their T
vedotin (EV) in combination with pembrolizumab
novel safety signals were identified
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production
antibody-dependent cellular cytotoxicity
apoptosis, and endocytosis
PD-L1)-positive
downregulation of p-Akt and Ki-67
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Junshi Biosciences
Toripalimab(Junshi Biosciences)은 Gastric Cancer 표적 항체로, Metastatic Colorectal Cancer; Liver Metastases 영역에서 개발·상용화 중입니다. 작용기전: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Phase 3 후기 임상 단계입니다. ClinicalTrials.gov 기준 93건의 관련 임상이 등록되어 있습니다. 차별점: novel safety signals were identified.
Gastric Cancer
Metastatic Colorectal Cancer; Liver Metastases
Recruiting
NK cells, increased circulating CD8+ Tem and Teff cells and their T
vedotin (EV) in combination with pembrolizumab
novel safety signals were identified
Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production
antibody-dependent cellular cytotoxicity
apoptosis, and endocytosis
PD-L1)-positive
downregulation of p-Akt and Ki-67
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.